Literature DB >> 28453614

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P Moreau1, J San Miguel2, P Sonneveld3, M V Mateos4, E Zamagni5, H Avet-Loiseau6, R Hajek7, M A Dimopoulos8, H Ludwig9, H Einsele10, S Zweegman11, T Facon12, M Cavo5, E Terpos8, H Goldschmidt13, M Attal6, C Buske14.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28453614     DOI： 10.1093/annonc/mdx096

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  166 in total

1.  Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.

Authors:  Shannon Cope; Kabirraaj Toor; Evan Popoff; Rafael Fonseca; Ola Landgren; María-Victoria Mateos; Katja Weisel; Jeroen Paul Jansen
Journal:  Value Health       Date:  2020-04-06       Impact factor: 5.725

2.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 3.  Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.

Authors:  Thierry Facon; Kenneth Anderson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Authors:  Kohmei Kubo; Mitsuo Hori; Kensuke Ohta; Hiroshi Handa; Kiyohiko Hatake; Morio Matsumoto; Shotaro Hagiwara; Kazuteru Ohashi; Chiaki Nakaseko; Kenshi Suzuki; Shigeki Ito; Gen Kinoshita; Suresh G Shelat; Masafumi Miyoshi; Naoki Takezako
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

Review 5.  Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

Authors:  Zaina T Al-Salama; Karly P Garnock-Jones; Lesley J Scott
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

6.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

7.  Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma.

Authors:  A M Sharma; M Sackett; D Bueddefeld; P Lambert; A Dubey; V Wadhwa; R Kotb; N Ahmed
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

8.  The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Ann Hematol       Date:  2020-10-29       Impact factor: 3.673

Review 9.  Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 10.  Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.